Listro, R; Stotani, S; Rossino, G; Rui, M; Malacrida, A; Cavaletti, G; Cortesi, M; Arienti, C; Tesei, A; Rossi, D; Di Giacomo, M; Miloso, M; Collina, S in [Listro, Roberta; Stotani, Silvia; Rossino, Giacomo; Rui, Marta; Rossi, Daniela; Di Giacomo, Marcello; Collina, Simona] Univ Pavia, Dept Drug Sci, Med Chem & Pharmaceut Technol Sect, Pavia, Italy; [Stotani, Silvia] Taros Chem GmbH & Co KG, Med Chem, Dortmund, Germany; [Malacrida, Alessio; Cavaletti, Guido; Miloso, Mariarosaria] Univ Milano Bicocca, Expt Neurol Unit, Sch Med & Surg, Monza, Italy; [Malacrida, Alessio; Cavaletti, Guido; Miloso, Mariarosaria] Univ Milano Bicocca, Milan Ctr Neurosci, Monza, Italy; [Cortesi, Michela; Arienti, Chiara; Tesei, Anna] Ist Sci Romagnolo Studio & Cura Tumori IRCCS, Biosci Lab, Meldola, Italy published Exploring the RC-106 Chemical Space: Design and Synthesis of Novel (E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents in 2020, Cited 65. SDS of cas: 385-00-2. The Name is 2,6-Difluorobenzoic acid. Through research, I have a further understanding and discovery of 385-00-2.
Despite the fact that significant advances in treatment of common cancers have been achieved over the years, orphan tumors still represent an important unmet medical need. Due to their complex multifactorial origin and limited number of cases, such pathologies often have very limited treatment options and poor prognosis. In the search for new anticancer agents, our group recently identifiedRC-106, a Sigma receptor modulator endowed with proteasome inhibition activity. This compound showed antiproliferative activity toward different cancer cell lines, among them glioblastoma (GB) and multiple myeloma (MM), two currently unmet medical conditions. In this work, we directed our efforts toward the exploration of chemical space aroundRC-106to identify new active compounds potentially useful in cancer treatment. Thanks to a combinatorial approach, we prepared 41 derivatives of the compound and evaluated their cytotoxic potential against MM and GB. Three novel potential anticancer agents have been identified.
Welcome to talk about 385-00-2, If you have any questions, you can contact Listro, R; Stotani, S; Rossino, G; Rui, M; Malacrida, A; Cavaletti, G; Cortesi, M; Arienti, C; Tesei, A; Rossi, D; Di Giacomo, M; Miloso, M; Collina, S or send Email.. SDS of cas: 385-00-2
Reference:
Isothiazole – Wikipedia,
,Isothiazole – ScienceDirect.com